<!DOCTYPE HTML>
<html lang="en">
<head>
	<meta charset="UTF-8">
	<title>VIKHI</title>
	<link rel="stylesheet" href="css/font-awesome/css/font-awesome.min.css" />

	<link rel="stylesheet" href="css/fonts/stylesheet.css" />
	<link rel="stylesheet" href="css/fonts/fonts.css" />
	<link rel="stylesheet" href="css/bootstrap/bootstrap.min.css" />
	<link rel="stylesheet" href="css/animat/animate.min.css" />
	<link rel="stylesheet" href="css/fancybox/jquery.fancybox.css" />
	<link rel="stylesheet" href="css/nivo-lightbox/nivo-lightbox.css" />
	<link rel="stylesheet" href="css/themes/default/default.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.carousel.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.theme.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.transitions.css">
	<link rel="stylesheet" href="css/style.css" />
	<link rel="stylesheet" href="css/responsive.css" />
	<link href="https://fonts.googleapis.com/css?family=Montserrat|Source+Sans+Pro" rel="stylesheet">
</head>
<body>

	<div class='preloader'><div class='loaded'>&nbsp;</div></div>

	<header id="home" class="header">
		<div class="main_menu_bg navbar-fixed-top">
			<div class="container">
				<div class="row">
					<div class="nave_menu">
					<nav class="navbar navbar-default">
					  <div class="container-fluid">
						<!-- Brand and toggle get grouped for better mobile display -->
						<div class="navbar-header">
						  <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#bs-example-navbar-collapse-1" aria-expanded="false">
						  </button>
						  <a class="navbar-brand" href="index.html">
							<div class="logo">
								<img src="images/vikhiLOGOsm.png" alt="" height="30"/>
							</div>
						  </a>
						</div>

						<!-- Collect the nav links, forms, and other content for toggling -->
						<div class="collapse navbar-collapse" id="bs-example-navbar-collapse-1">

						  <ul class="nav navbar-nav navbar-right">
							<li><a href="aspectos.html">1. General Aspects</a></li>
							<li><a href="recomendaciones.html">2. Recommendations</a></li>
							<li class="active"><a href="toxicidad00.html">3. Toxicities</a></li>
						  </ul>
						</div><!-- /.navbar-collapse -->
					  </div><!-- /.container-fluid -->
					</nav>
					</div>
				</div><!--Fin de row -->

			</div><!--Fin de container -->

		</div>
	</header> <!--Fin de header -->



	<section class="banner">
		<div class="container">
			<div class="row">
				<div class="main_banner_area text-center">
					<div class="col-md-12 col-sm-12">
						<div class="single_banner_text wow zoomIn" data-wow-duration="1s">
							<h2>Toxicities</h2>
							<br/>
							<div class="separator"></div>
							<h5>BASIC COURSE IN IMMUNOTHERAPY</h5>


						</div>
					</div>
				</div>
			</div>
		</div>
	</section><!-- Fin de Banner Section -->




	<section class="franja">
	 <div class="overlay_franja">
		 <div class="container">
			 <div class="row">
				 <div class="col-md-12 col-sm-12 col-xs-12">
					 <div class="main_franja_content text-center wow fadeIn" data-wow-duration="2s">
						 <h2>3<span class="negrita">.5</span> ENDOCRINE TOXICITY</h2>
						 <br/> <img src="images/endo.png" alt="" height="50px"/>

					 </div>
				 </div>
			 </div>
		 </div>
	 </div>
 </section>
 <section class="texto">
	 <div class="container">
		 <div class="row">
			 <div class="parrafo wow zoomIn" data-wow-duration="0.5s">
				 <p>The most frequent endocrine toxicities associated with immune checkpoint inhibitors are thyroiditis, hypophysitis and adrenal insufficiency, but there are also others such as low testosterone levels, type I diabetes mellitus or primary adrenal insufficiency (Corseal, The Journal of Clinical Endocrinology and Metabolism, 2013).</p>
				 <p>The presence of secondary effector T cells as a consequence of immunotherapy induces autoimmunity in the tissues through direct cytotoxicity mediated by autoantigens, with the development of T cell-dependent autoantibodies, with the consequent damage and appearance of inflammation. The reason why the checkpoint inhibition targets the pituitary and the adrenal glands is not clear. The significant vascularisation of these glands can play a role.</p>
				 <p>Strict follow-up of these patients is therefore recommended. It is recommended that thyroid function is checked before each cycle and repeated every 6-12 weeks for the first 6 months after completion of treatment, as well as ACTH, cortisol and testosterone (in men).</p>
				 <p>3-20% of patients treated with anti-CTLA4 have a complication of this type (Joshi, Clin Endocrinology 2016). The most common are: hypophysitis, thyroiditis and adrenal insufficiency. They usually appear 9 weeks after starting treatment. Anti PD1 / PDL1 treatment can also cause them in 5-20%, although they are usually later (between weeks 12 and 24). The combination of Ipilimumab and Nivolumab can cause up to 8% of hypophysitis (Ryder, Endocrine-Related Cancer 2014).</p>
				 <p>Hyper or hypothyroidism occurs in 10-15% of cases. The combination of Ipilimumab and Nivolumab may produce hypothyroidism in 15% of cases, compared to 4-10% with anti-PD1 agents alone or 2–4% with Ipilimumab. Hyperthyroidism is much more rare, with an incidence of 1-7% (Joshi, Clin Endocrinology 2016).</p>
				 <p>Frequently, hyperthyroidism precedes a long period of hypothyroidism. Resolution of this toxicity may take between 6 and 10 months.</p>
			 </div>
		 </div>
	 </div>
 </section>

	<section class="counterUp">
		<div class="counter_overlay">
			<div class="container">
				<div class="row">
					<div class="main_counter_content text-center">
						<div class="col-md-12 col-sm-12 col-xs-12">


							<h2>CASE REPORT 1:</h2>
							<br/> <img src="images/pacienteICON.png" alt="" height="40px"/> <br/> <br/> <br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> A 69-year-old patient, allergic to heparin, penicillin, HT and DLP, depressive Sd, controlled hyperferritinemia due to LCH, fibular osteosynthesis due to accidental fracture.</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Left nephrectomy for clear renal cell carcinoma pT2pNx (H. M. Broggi) 5 years ago. Current mediastinal and CNS lymph node recurrence.</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Treatment: 15/12/16 SRS radiosurgery 20.00 Gy M1 frontal right only.</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> 01/16/17 Sunitinib initiated at full dose with significant toxicity requiring gradual dose reductions, C5 at dose of 25 and C6 dose of 25 but alternative 2:1 regimen. Sutent STOPPED on 12/12/17 due to PD and poor tolerance.</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> CT scan on 02/02/18: Progression. We proposed CE Lenva 2 dose + everolimus, which the patient accepted. The Informed Consent Form was signed on 09/02/18.</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> 21/02/18 started C1 treatment with Lenva + everolimus.</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> November 2018 Mediastinal lymph node progression Started Nivolumab 3 mg/kg every 2 weeks.</p>
							<br/><br/> <img src="images/medicinas.png" alt="" height="40px"/> <br/>
							<p><span class="negrita">At the 7th cycle:</span></p>
							<br/>
							<p class="izquierda">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Normal baseline TSH</p>
							<br/>
							<p class="izquierda">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; TSH before the third administration (4 weeks) 0.03 mlU / mL with </p>
							<br/>
							<p class="izquierda">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; normal T3 and T4</p>
							<br/>
							<p class="izquierda">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; TSH at 6 weeks TSH 34.01 mlU/ml, free T4 undetectable</p>
							<p class="izquierda">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The patient reports worsening of his usual asthenia from GRADE 1 to GRADE 2</p>

						</div>
					</div>
				</div>
			</div>
		</div>
	</section>


	<section class="tabla">
		<div class="container">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">


							<p>Hypothyroidism is usually subclinical or mildly symptomatic. In less than 1% of cases it leads to severe symptoms or is life threatening. Some of these symptoms include: asthenia, constipation, weight gain, loss of appetite, xerosis, facial oedema, and less frequently, bradycardia, hypotension, pericardial effusion, depression, hypoventilation, stupor, lethargy and coma.</p>
							<br/>
							<p>Hyperthyroidism, unlike thyrotoxicosis due to autoimmune thyroiditis, is an entity in which the increase in thyroid hormones is due to hyperstimulation of the thyroid.</p>
							<br/>
							<p>Autoimmune thyroiditis and hyperthyroidism have the same symptoms: tachycardia, arrhythmia, nervousness, palpitations, sweating, heat intolerance, muscle fatigue, diarrhoea, and weight loss despite increased appetite.</p>
							<br/>
							<p>The diagnosis of this condition is based on <span class="negrita">:</span></p>
							<br/>
							<p><span class="negrita">•</span> Tests: TSH, T4, T3, anti-thyroglobulin antibodies, anti-TPO, anti-TSHR</p>
							<br/>
							<p><span class="negrita">•</span> Thyroid ultrasound</p>
							<br/>
							<p><span class="negrita">•</span> Thyroid scintigraphy</p>
							<br/> <br/> <br/>
							<h2>How do we define endocrine toxicity in the thyroid?</h2>
							<br/>
							<p>The grades of endocrine toxicity are defined according to the <span class="cursiva">Common Terminology Criteria for Adverse Events</span> (CTCAE), <span class="cursiva">Version 4.0</span> (CTCAE v4)</p>
							<br/>
							<table class="vikhi-tabla">
							<tr>
								<th><p></p></th>
								<th><p>Hypothyroidism</p></th>
								<th><p>Hyperthyroidism</p></th>
							</tr>
							<tr>
								<td><p>GRADE 1</p></td>
								<td><p><span class="negrita">•</span> Asymptomatic or mild symptoms</p><p><span class="negrita">•</span> T3, T4 normal</p><p><span class="negrita">•</span> TSH &gt;10</p><p><span class="negrita">•</span> anti-TPO and anti-TG generally high</p></td>
								<td><p><span class="negrita">•</span> Asymptomatic or mild symptoms</p><p><span class="negrita">•</span> T3, T4 normal</p><p><span class="negrita">•</span> TSH &lt;0.3</p><p><span class="negrita">•</span> anti-TPO and/or anti-TG normal or high</p></td>
							</tr>
							<tr>
								<td><p>GRADE 2</p></td>
								<td><p><span class="negrita">•</span> Moderate symptoms. They do not affect daily living activities</p><p><span class="negrita">•</span> T3 and/or T4 low</p><p><span class="negrita">•</span> TSH &gt;10</p><p><span class="negrita">•</span> anti-TPO and anti-TG generally high</p></td>
								<td><p><span class="negrita">•</span> Moderate symptoms. They do not affect daily living activities</p><p><span class="negrita">•</span> T3 and/or T4 high</p><p><span class="negrita">•</span> TSH &lt; 0.1</p><p><span class="negrita">•</span> anti-TPO and anti-TG variable (generally high), anti-TSHR high in Graves-Basedow.</p></td>
							</tr>
							<tr>
								<td><p>GRADE 3</p></td>
								<td><p><span class="negrita"></span> Severe but not life-threatening symptoms; hospitalisation required; daily living activities affected</p><p><span class="negrita">•</span> T3 and/or T4 very low</p><p><span class="negrita">•</span> TSH very high</p><p><span class="negrita">•</span> anti-TPO and anti-TG high</p></td>
								<td><p><span class="negrita"></span> Severe but not life-threatening symptoms; hospitalisation required; daily living activities affected</p><p><span class="negrita">•</span> Daily living activities not affected</p><p><span class="negrita">•</span> T3 and T4 high</p><p><span class="negrita">•</span> TSH &lt; 0.1</p>
									<p><span class="negrita">•</span> anti-TPO and anti-TG high, anti-TSHR high in Graves-Basedow</p></td>
							</tr>
							<tr>
								<td><p>GRADE 4</p></td>
								<td><p><span class="negrita">•</span> Life-threatening consequences</p></td>
								<td><p><span class="negrita">•</span> T3 and T4 high</p><p><span class="negrita">•</span> TSH &lt; 0.1</p><p><span class="negrita">•</span> anti-TPO and anti-TG high, anti-TSHR high in Graves-Basedow</p></td>
							</tr>
							</table>

						</div>
					</div>
				</div>
			</div>
		</div>
	</section>


	<section class="counterUp">
		<div class="counter_overlay">
			<div class="container">
				<div class="row">
				<div class="main_counter_content text-center">
				<div class="col-md-12 col-sm-12 col-xs-12">






					<div class="marcoOSCURO wow fadeIn">

					<form>
					<br/> <br/> <br/>
					<P>It seems that our patient has had autoimmune thyroiditis due to immunotherapy that has evolved to hypothyroidism...</P>
					<br/>

					<h2>What would the next steps be?</h2>
					<br/> <br/> <br/> <br/>
					<label class="container">I would monitor the thyroid hormones and strictly control the situation.
						<input type="radio" name="pregunta1" id="p2">
						<span class="checkmark"></span>
					</label>
					<br/>
					<label class="container">I would start Levothyroxine, continue the Nivolumab and this would be strictly monitored.
						<input type="radio" name="pregunta1" id="p1">
						<span class="checkmark"></span>
					</label>
					<br/>
					<label class="container">I would start Levothyroxine, stop the Nivolumab and it would be strictly monitored.
						<input type="radio" name="pregunta1" id="p3">
						<span class="checkmark"></span>
					</label>
					<br/>
					<label class="container">I would reintroduce Nivolumab upon normalisation of thyroid function.
						<input type="radio" name="pregunta1" id="p4">
						<span class="checkmark"></span>
					</label>
					<br/>
					<label class="container">I would start Levothyroxine, stop Nivolumab, start corticosteroid therapy and it would be strictly monitored.
						<input type="radio" name="pregunta1" id="p5">
						<span class="checkmark"></span>
					</label>
					<br/>
					<label class="container">I would reintroduce Nivolumab upon normalisation of thyroid function and decrease the corticosteroid dose.
						<input type="radio" name="pregunta1" id="p6">
						<span class="checkmark"></span>
					</label>
					</form>

					<div class="pregunta wow fadeIn" data-wow-duration="1s">
						<a href="#"><img onclick="resultado();return false;" src="images/profesora.png" alt="" height="90px"/></a>
					</div>


						<div id="flotante" style="display:none;">


							<br/><br/><h2>Correct!</h2>
							<br/>
							<h2>The correct therapeutic decision would be<span class="negrita">:</span></h2>
							<br/> <br/>
							<p><span class="negrita">•</span> It became GRADE 2 hypothyroidism after a phase of silent thyrotoxicosis.</p>
							<br/>
							<p><span class="negrita">•</span> Antithyroglobulin antibodies were determined at &gt;1000 U/Ml (0-9.9 U/ml), anti-TPO 344.8 U/Ml (0-5.9 U/mL), suggesting a primary hypothyroidism.</p>
							<br/><p><span class="negrita">•</span> Levothyroxine was started and Nivolumab was continued.</p>
							<br/><p><span class="negrita">•</span> At 8 weeks, TSH decreased to 5.54 mlU/mL with normal free T4, and at 27 weeks TSH already showed normal levels (2.32 mlU/mL).</p>
							<br/><p><span class="negrita">•</span> The patient continues to be treated with Nivolumab after 9 months of treatment, with a complete pulmonary response.</p>



						</div>
						<div id="flotanteIncorrecto" style="display:none;">
							<br/><br/>
							<h2>This is not correct. Try again :)</h2>

						</div>


					</div>






			</div>
		</div>
	</section>

	<section class="texto">
		<div class="container">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">

					<h2>Management of endocrine-related toxicity in thyroid</h2>
					<br/>
					<p class="cursiva">(Gridelli, Journal of Endocrinology and Diabetes 2016, Champiat AnnOncol 2016, Friedman, JAMA Oncol 2016, Weber JCO 2012, Kumar Front Pharmacol 2017, Linardou Ann Translat Medicine 2016, Bristol-Myers REMS 2012, Haanen, Ann Oncol. 2017; Thompson. J Natl Compr Canc Netw. 2018; Brahmer. J Clin Oncol. 2018)</p>
					<br/>
					<p>The treatment of hyperthyroidism is based on simple measures such as avoiding iodised salts, rinses, toothpastes or drugs containing iodine. </p>
					<br/>
					<p>In cases of Graves-Basedow disease, treatment with Methimazole is recommended and more recent data assess the use of selenium in mild/moderate forms.  </p>
					<br/>
					<p>The use of intravenous corticosteroids at high doses is only indicated in severe cases of Graves-Basedow with diplopia, optic neuropathy and proptosis.</p>
					<br/>
					<p>The time to resolution of thyroid toxicity is not well-established and it may still be permanent in many cases.</p>
					<br/>
					<p>To summarise <span class="negrita">:</span></p>
					<br/>

				<table class="vikhi-tablaSM">
					<tr>
						<th><p></p></th>
						<th><p>Levothyroxine</p></th>
						<th><p>Beta blockers</p></th>
						<th><p>Thyrostatics (Methimazole)</p></th>
						<th><p>Corticosteroids</p></th>
						<th><p>Management</p></th>
					</tr>
					<tr>
						<td><p>Euthyroid thyroiditis</p></td>
						<td><p>No</p></td>
						<td width="20%"><p>No</p></td>
						<td><p>No</p></td>
						<td width="20%"><p>No</p></td>
						<td width="35%"><p><span class="negrita">•</span> TSH, T3, T4, anti-TPO, baseline anti-TG</p><p><span class="negrita">•</span> TSH, before each cycle</p></td>
					</tr>
					<tr>
						<td><p>Subclinical hypothyroidism</p></td>
						<td><p>If TSH &gt;10</p></td>
						<td><p>No</p></td>
						<td><p>No</p></td>
						<td><p>No</p></td>
						<td><p><span class="negrita">•</span> TSH, T3, T4, anti-TPO, baseline anti-TG</p><p><span class="negrita">•</span> TSH, T3, T4 before each cycle</p></td>
					</tr>
					<tr>
						<td><p>Primary hypothyroidism</p></td>
						<td><p>Yes</p></td>
						<td><p>No</p></td>
						<td><p>No</p></td>
						<td><p>No</p></td>
						<td><p><span class="negrita">•</span> TSH, T3, T4, anti-TPO, baseline anti-TG</p><p><span class="negrita">•</span> TSH, T3, T4 before each cycle</p></td>
					</tr>
					<tr>
						<td><p>Secondary hypothyroidism</p></td>
						<td><p>Yes</p></td>
						<td><p>No</p></td>
						<td><p>No</p></td>
						<td><p>No</p></td>
						<td><p><span class="negrita">•</span> TSH, T3, T4, anti-TPO, anti-TG, cortisol levels in urine at 24 hours, PRL, LH, FSH, baseline ACTH</p><p>cortisol, T3, T4 before each cycle and others if applicable</p></td>
					</tr>
					<tr>
						<td><p>Subclinical hyperthyroidism</p></td>
						<td><p>No</p></td>
						<td><p>If symptoms are mild</p></td>
						<td><p>No</p></td>
						<td><p>No</p></td>
						<td><p><span class="negrita">•</span> TSH, T3, T4, anti-TPO, anti-TG, baseline TSAbs</p><p><span class="negrita">•</span> TSH, T3, T4 before each cycle</p><p><span class="negrita">•</span> Avoid iodised salt, drugs, rinses and toothpastes that contain iodine</p></td>
					</tr>
					<tr>
						<td><p>Clinical hyperthyroidism</p></td>
						<td><p>No</p></td>
						<td><p>In the first phase, until the thyrostatic effect of the treatment is obtained</p></td>
						<td><p>Yes</p></td>
						<td><p>In GRADE 3-4 hyperthyroidism or in severe forms of Graves' ophthalmopathy</p></td>
						<td><p><span class="negrita">•</span> TSH, T3, T4, anti-TPO, anti-TG, baseline TSAbs</p><p><span class="negrita">•</span> TSH, T3, T4 before each cycle</p><p><span class="negrita">•</span> Avoid iodised salt, drugs, rinses and toothpastes that contain iodine</p></td>
					</tr>
					</table>
				</div>
			</div>
		</div>
	</section>


	<section class="texto">
		<div class="container">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">
				</div>
			</div>
		</div>
	</section>




	<section class="counterUp">
		<div class="counter_overlay">
			<div class="container">
				<div class="row">
					<div class="main_counter_content text-center">
						<div class="col-md-12 col-sm-12 col-xs-12">


							<h2>CLINICAL CASE 2</h2>
							<br/> <img src="images/pacienteICON.png" alt="" height="40px"/> <br/> <br/> <br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> 58-year-old patient, ex-smoker, with a history of type II diabetes mellitus on treatment with Glimepiride, mild chronic kidney failure and depressive syndrome treated with Citalopram and Lormetazepam.</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Squamous cell carcinoma of the right tonsil with bilateral enlarged lymph nodes at level II, bilateral axillary and prevascular mediastinal and subcarinal lymph nodes p16 negative (cT3N2cM1). Chemotherapy was performed with carboplatin/5 Fluorouracil/ Cetuximab for 5 cycles, after which chemotherapy was suspended due to severe haematological toxicity and maintenance Cetuximab was started.</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Lymph node progression at all levels 3 months after starting maintenance Cetuximab. Weekly Paclitaxel started, with a new progression at 3 months.</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> The patient started Nivolumab 3 mg/kg every 2 weeks.</p>

							<br/> <br/> <img src="images/medicinas.png" alt="" height="40px"/> <br/>
							<p><span class="negrita">Partial response after 8 cycles:</span></p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Admitted to the hospitalisation facility with GRADE 2 asthenia of </p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> one week progression, anorexia, weight loss and joint pain</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Blood tests: creatinine 1.78 mg/dl, normal electrolytes, TSH 3.9, cortisol 0.1 micrograms/dl</p>

						</div>
					</div>
				</div>
			</div>
		</div>
	</section>

	<section class="texto">
		<div class="container">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">

					<p>Symptoms of hypophysitis are usually quite specific (headache, asthenia, weakness, memory loss, impotence, changes in personality, changes in visual fields, amenorrhoea and impotence, etc.), so diagnostic suspicion is required.</p>
					<br/><p>They rarely start before 6 weeks, and sometimes they start very late (Joshi, Clinical Endocrinology 2016).</p>
					<br/><p>The symptoms are so non-specific that they can be confused with the derivative of the cancer itself, which is why we must keep this fact in mind and monitor it.</p>
					<br/><p>For the diagnosis of hypophysitis we must perform:</p>
					<br/><p><span class="negrita">•</span> Complete blood count: TSH, T3, T4, cortisol, stimulation test, LH, FSH, prolactin, testosterone in males and oestradiol in women</p>
					<br/><p><span class="negrita">•</span> Brain MRI</p>



				</div>
			</div>
		</div>
	</section>


	<section class="counterUp">
		<div class="counter_overlay">
			<div class="container">
				<div class="row">
				<div class="main_counter_content text-center">
				<div class="col-md-12 col-sm-12 col-xs-12">

					<div class="marcoOSCURO wow fadeIn">
					<p>Given the suspicion of hypophysitis, in the case of our patient, the tests were completed showing <span class="negrita">:</span></p>
					<br/><br/>
					<p><span class="negrita">•</span> Free T4 0.55 ng/dL (0.7-1.48)</p>
					<br/>
					<p><span class="negrita">•</span> LH/FSH normal</p>
					<br/>
					<p><span class="negrita">•</span> PRL high, 22.8 ng/mL (4-13.4)</p>
					<br/>
					<p><span class="negrita">•</span> Testosterone low 56.1 ng/dL (220-715)</p>
					<br/>
					<p><span class="negrita">•</span> Somatotropin low &lt; 0.05 micrograms/L</p>
					<br/>
					<p><span class="negrita">•</span> ACTH 6.7 pg/mL (5-46)</p>
					</div>
<br/>
					<div class="marcoOSCURO wow fadeIn">
					<p>An MRI of the pituitary gland was requested <span class="negrita">:</span></p>
					<br/><br/>
					<p><span class="negrita">•</span> Slight increase in the size of the pituitary gland 11x6x10.5 with slightly heterogeneous contrast enhancement and uptake of the pituitary stalk that extends to the hypothalamic floor slightly more than normal</p>
					</div>
<br/>
					<div class="marcoOSCURO wow fadeIn">
					<p>Given the orientation of hypophysitis to GRADE 2-3, assessment by the Endocrinology Department is requested, and <span class="negrita">:</span></p>
					<br/><br/>
					<p><span class="negrita">•</span> Intravenous Hidroaltesone is started, 100 mg/24 hours</p>
					<br/>
					<p><span class="negrita">•</span> Levothyroxine, started with dose of 50 micrograms/day, one week after the start of Hidroaltesone</p>
					<br/>
					<p><span class="negrita">•</span> Intramuscular testosterone 250 mg/3 weeks</p>
					</div>

			</div>
		</div>
	</section>

	<section class="texto">
		<div class="container">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">

					<h2>Management of endocrine-based toxicity</h2>
					<br/>
					<p class="cursiva">(Joshi, Clinical Endocrinology 2016, Champiat Ann Oncol 2016, Friedman, JAMA Oncol 2016, Weber JCO 2012, Bristol-Myers REMS 2012, Haanen, Ann Oncol. 2017; Thompson. J Natl Compr Canc Netw. 2018; Brahmer. J Clin Oncol. 2018)</p>
					<br/> <br/>

				<table class="vikhi-tablaSM">
					<tr>
						<th><p>GRADE</p></th>
						<th><p>Clinical</p></th>
						<th><p>Hormone test</p></th>
						<th><p>Management</p></th>
						<th><p>Follow-up</p></th>
					</tr>
					<tr>
						<td><p>1</p></td>
						<td><p><span class="negrita">Asymptomatic or mild symptoms</span></p><p><span class="negrita">•</span> Asthenia, nausea</p></td>
						<td><p><span class="negrita">•</span> 24-hour urine cortisol low, but normal RM close to normal</p></td>
						<td><p><span class="negrita">•</span> Symptomatic treatment</p></td>
						<td><p><span class="negrita">•</span> 24-hour urine cortisol, TSH, ACTH and plasma cortisol before each cycle</p></td>
					</tr>
					<tr>
						<td><p>2</p></td>
						<td><p><span class="negrita">Symptoms of panhypopituitarism</span></p><p><span class="negrita">•</span> Asthenia, muscle weakness, vomiting, hypoglycaemia, anaemia, nausea, depression, constipation, xerosis, bradycardia, lethargy, decreased libido, erectile dysfunction</p></td>
						<td><p><span class="negrita">•</span> 24-hour urine cortisol low, ACTH and plasma cortisol low</p><p><span class="negrita">•</span> TSH, T3, T4 low</p><p><span class="negrita">•</span> LH and FSH low</p><p><span class="negrita">•</span> MRI: homogeneous enhancement of the pituitary gland after gadolinium injection</p></td>
						<td><p><span class="negrita">•</span> Hormone replacement therapy</p><p><span class="negrita">•</span> Levothyroxine if necessary with strict monitoring</p><p><span class="negrita">•</span> Oral corticosteroids</p></td>
						<td><p><span class="negrita">•</span> Cortisol in urine at 24 hours</p><p><span class="negrita">•</span> TSH, T3, T4, PRL, LH, FSH. ACTH and plasma cortisol before each cycle</p></td>
					</tr>
					<tr>
						<td><p>3</p></td>
						<td><p><span class="negrita">Symptoms of panhypopituitarism and a mass effect with no life hazard</span></p><p><span class="negrita">•</span> Headache, asthenia, emesis, vertigo, visual disturbances, diplopia</p></td>
						<td><p><span class="negrita">•</span> 24-hour urine cortisol low, ACTH and plasma cortisol low</p><p><span class="negrita">•</span> TSH, T3, T4 low</p><p><span class="negrita">•</span> LH and FSH low</p><p><span class="negrita">•</span> MRI: increase in the size of the pituitary gland, with suprasellar extension, which can affect the optic nerve</p></td>
						<td><p><span class="negrita">•</span> Hospitalisation</p><p><span class="negrita">•</span> Levothyroxine if necessary with strict monitoring</p><p><span class="negrita">•</span> Intravenous corticosteroids at high doses: Methylprednisolone (1-2 mg/kg/day) 5 days and then oral prednisone (1-2 mg/kg/day)</p><p><span class="negrita">•</span> Discontinuation of immunotherapy</p></td>
						<td><p><span class="negrita">•</span> Repeat MRI after 6 days of IV corticosteroids If the pituitary gland size and secondary symptoms have decreased, consider restarting immunotherapy without withdrawing corticosteroid therapy</p></td>
					</tr>
					<tr>
						<td><p>4</p></td>
						<td><p><span class="negrita">Symptoms of panhypopituitarism and mass effect with life hazard</span></p><p><span class="negrita">•</span> Headache, asthenia, emesis, vertigo, visual disturbances, diplopia</p></td>
						<td><p><span class="negrita">•</span> 24-hour urine cortisol low, ACTH and plasma cortisol low</p><p><span class="negrita">•</span> TSH, T3, T4 low</p><p><span class="negrita">•</span> LH and FSH low</p><p><span class="negrita">•</span> MRI: increase in the size of the pituitary gland, with suprasellar extension, which can affect the optic nerve</p></td>
						<td><p><span class="negrita">•</span> Hospitalisation</p><p><span class="negrita">•</span> Levothyroxine if necessary with strict monitoring</p><p><span class="negrita">•</span> Intravenous corticosteroids at high doses: Methylprednisolone (1-2 mg/kg/day) 5 days and then oral prednisone (1-2 mg/kg/day)</p><p><span class="negrita">•</span> Discontinuation of immunotherapy</p><p><span class="negrita">•</span> Life support measures
						</p></td>
						<td><p><span class="negrita">•</span> Repeat MRI after 6 days of IV corticosteroids If the pituitary gland size and secondary symptoms have decreased, consider restarting immunotherapy without withdrawing corticosteroid therapy</p></td>
					</tr>
					</table>
					<br/>
					<p>In the treatment of hypophysitis, it is important that cortisol replacement therapy be started one week before Levothyroxine, so as not to precipitate an adrenal crisis.</p>

				</div>
			</div>
		</div>
	</section>

	<section class="counterUp">
		<div class="counter_overlay">
			<div class="container">
				<div class="row">
					<div class="main_counter_content text-center">
						<div class="col-md-12 col-sm-12 col-xs-12">
							<img src="images/medicinas.png" alt="" height="40px"/> <br/><br/>

							<p>24 hours after initiating replacement therapy, the patient’s asthenia and appetite improved. The patient was discharged with a decreasing regimen of corticosteroid therapy with oral hydralazine, oral levothyroxine and intramuscular testosterone.</p>
							<br/>
							<p>It was decided to continue the Nivolumab</p>
							<br/>
							<p>So far, 34 cycles have been completed and partial response persists.</p>
							<br/>
							<p>The patient still requires replacement treatment with:</p>
							<br/>

							<p><span class="negrita">•</span> Hidraltesone 20 mg- 10 mg- 5 mg.</p>
							<br/>
							<p><span class="negrita">•</span> Levothyroxine 150 micrograms/day.</p>
							<br/>
							<p><span class="negrita">•</span> Intramuscular testosterone 250 mg/3 weeks</p>
							<br/>
							<p>Partial response persists</p>


						</div>
					</div>
				</div>
			</div>
		</div>
	</section>

	<section class="texto">
		<div class="container">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">

					<p>It is common to detect clinical and radiological improvement within a few days, but the mean time for symptom resolution and hormone therapy withdrawal may be more than 20 weeks.</p>
					<br/><p>They should be informed of the possibility of permanent hypogonadism or secondary hypothyroidism in 50% of cases (Torino, European Journal of Endocrinology/ European Federation of Endocrine Societies 2013).</p>
					<br/><p>A recent study shows that TSH and FSH normalised after a follow-up period of 33 months, but ACTH remains low and the abnormalities were still seen on the MRI (Albarel, Eur J Endocrinol, 2015; Min, Clin Cancer Res, 2015). Despite that, the resolution time for thyroid toxicity is still not well established, and in many cases it may be permanent.</p>
					<br/><p>The relationship to response to treatment is not clear. The use of corticosteroid therapy was also not related to a change in the natural history of the disease. It has not been demonstrated to influence worse overall survival</p>
					<br/><br/><br/>
					<h2>Management of adrenal endocrine toxicity</h2>
					<br/>
					<p>Primary adrenal insufficiency or Addison's disease, without hypophysitis, is related to the development of anti-adrenal antibodies.</p>
					<p>The symptoms related to this pathology include asthenia, anhedonia, anorexia, nausea, vomiting, fever, coma, hypotension, hypoglycaemia and eosinophilia.</p>
					<p>The acute establishment of this severe-grade toxicity is known as Addisonian crisis.</p>
					<p>Below we describe the different grades and management of this type of toxicity (Joshi, Clinical Endocrinology 2016, Champiat Ann Oncol 2016, Kumar Frontiers in Pharmacology 2017, Bristol-Myers REMS 2012, Haanen, Ann Oncol. 2017; Thompson. J Natl Compr Canc Netw. 2018; Brahmer. J Clin Oncol. 2018)</p>
					<br/><br/><br/>
					<h2>Management of primary adrenal insufficiency</h2>
					<br/><br/>

					<table class="vikhi-tablaSM">
						<tr>
							<th><p>Grade</p></th>
							<th><p>Clinical</p></th>
							<th><p>Hormone test</p></th>
							<th><p>Management</p></th>
							<th><p>Follow-up</p></th>
						</tr>
						<tr>
							<td><p>1</p></td>
							<td><p><span class="negrita">Asymptomatic or mild symptoms</span></p><p><span class="negrita">•</span> Muscle weakness, fatigue and orthostatic hypotension</p></td>
							<td><p> <span class="negrita">•</span> 24-hour urine cortisol low, but close to normal</p><p><span class="negrita">•</span> Fasting hypoglycaemia</p></td>
							<td><p><span class="negrita">•</span> Oral hydrocortisone (30 mg/day in 2-3 doses) or prednisone 5-7.5 mg/day in one dose in the morning</p></td>
							<td><p><span class="negrita">•</span> 24-hour urine cortisol, TSH, ACTH, cortisol and plasma renin activity before each cycle (if under treatment, take the sample at least 24 hours after the last administration of corticosteroids) BUN, glucose and electrolytes before each cycle</p></td>
						</tr>
						<tr>
							<td><p>2</p></td>
							<td><p><span class="negrita">Moderate symptoms</span></p><p><span class="negrita">•</span> Asthenia, muscle weakness, anorexia, nausea, vomiting and diarrhoea, orthostatic hypotension, poor tolerance to cold, hyperpigmentation</p></td>
							<td><p><span class="negrita">•</span> 24-hour urine cortisol low. Renin activity in plasma and increased ACTH and low cortisol</p><p><span class="negrita">•</span> Hyponatremia (&lt;130mEq/l) Hyperkalaemia (&gt; 5mEq/l) Na ratio: Serum K &lt;30: 1 fasting hypoglycaemia (&lt; 50 mg/dl)</p></td>
							<td><p><span class="negrita">•</span> Oral hydrocortisone (30 mg/day in 2-3 doses) or prednisone 5-7.5 mg/day in one dose in the morning</p><p><span class="negrita">•</span> In case of vomiting, dexamethasone 4 mg/day IM</p><p><span class="negrita">•</span> Fludrocortisone acetate (0.1 mg/day in one dose in the morning).</p></td>
							<td><p><span class="negrita">•</span> 24-hour urine cortisol, TSH, ACTH, cortisol and plasma renin activity before each cycle (if under treatment, take the sample at least 24 hours after the last administration of corticosteroids) BUN, glucose and electrolytes before each cycle</p></td>
						</tr>
						<tr>
							<td><p>3</p></td>
							<td><p><span class="negrita">Severe symptoms but not life-threatening</span></p><p><span class="negrita">•</span> Hypotension, dizziness, bradycardia, vomiting, diarrhoea, asthenia, weight loss, dehydration, hyperpigmentation</p></td>
							<td><p><span class="negrita">•</span> Same as GRADE 2</p><p><span class="negrita">•</span> Increased haematocrit</p><p><span class="negrita">•</span> Increase in plasma bicarbonate</p><p><span class="negrita">•</span> (&gt;28 mEq/l) Increased BUN (&gt;20 mg/dl)</p></td>
							<td><p><span class="negrita">•</span> Hydrocortisone 50 mg IM or IV in 24-hour continuous infusion</p><p><span class="negrita">•</span> Discontinue immunotherapy</p></td>
							<td><p><span class="negrita">•</span> Once vital signs improve, hormone levels normalise and oral corticosteroid therapy is established, consider restarting immunotherapy</p></td>
						</tr>
						<tr>
							<td><p>4</p></td>
							<td><p><span class="negrita">Severe symptoms, life-threatening</span></p><p><span class="negrita">•</span> Addisonian crisis</p><p><span class="negrita">•</span> Severe weakness, significant pain in abdomen, lower back, legs, hypotension, bradycardia, peripheral vascular collapse, acute renal failure</p></td>
							<td><p><span class="negrita">•</span> As with GRADE 3, metabolic acidosis, increased creatinine </p></td>
							<td><p><span class="negrita">•</span> Hospitalisation</p><p><span class="negrita">•</span> Discontinue immunotherapy</p><p><span class="negrita">•</span> Hydrocortisone 200 mg IV every 6 hours</p><p><span class="negrita">•</span> Treatment of hypovolaemia, dehydration, electrolyte disorders</p><p><span class="negrita">•</span> If necessary, vasoconstrictors until hydrocortisone exerts its effect
							</p><p><span class="negrita">•</span> During the second 24 hours, 150 mg of hydrocortisone is administered followed by 75 mg on the 3rd day</p><p><span class="negrita">•</span> Maintenance treatment is 30 mg hydrocortisone and 0.1 mg oral fludrocortisone acetate</td>
							<td><p><span class="negrita">•</span> Once vital signs improve, hormone levels normalise and oral corticosteroid therapy is established, consider restarting immunotherapy</p></td>
						</tr>
						</table>
						<br/>
						<p>Treatment is based on hormone replacement.</p>
						<br/>
						<p>Early onset of improves symptomatology and enables the continuation of immunotherapy, although hormone secretion may not be recovered completely.</p>
				</div>
			</div>
		</div>
	</section>






	<section>
	 <div class="container">
		 <div class="row">

			 <div class="wedo_content_area">

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad01.html"><h4 class="gris">3.1 GASTROINTESTINAL TOX.</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad02.html"><h4 class="gris">3.2 PULMONARY TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad03.html"><h4 class="gris">3.3 RENAL TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad04.html"><h4 class="gris">3.4 LIVER TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad05.html"><h4 class="gris">3.5 ENDOCRINE TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contorno wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad06.html"><h4>3<span class="turquesa">.6</span> CUTANEOUS TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contorno wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad07.html"><h4>3<span class="turquesa">.7</span> NEUROLOGICAL TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contorno wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad08.html"><h4>3<span class="turquesa">.8</span> OTHER TOXICITIES</h4></a>
						 </div>
					 </div>
				 </div>
			 </div>
		 </div>
	 </div>
	</section>


	<footer id="footer" class="footer">
		<div class="container">
			<div class="row">
				<div class="main_footer text-center wow zoomIn" data-wow-duration="1s">
					<p class="centrado"><a href="https://www.e-oncologia.org/"><img src="images/LOGOeonco.png" alt="" height="22px"/></a></p>
				</div>
			</div>
		</div>
	</footer>

	<!-- STRAT SCROLL TO TOP -->

	<div class="scrollup">
		<a href="#"><img src="images/up.png" alt=""/></a>
	</div>






	<script type="text/javascript" src="js/jquery/jquery.js"></script>

	<script type="text/javascript" src="js/script.js"></script>

	<script type="text/javascript" src="js/bootstrap/bootstrap.min.js"></script>

	<script type="text/javascript" src="js/fancybox/jquery.fancybox.pack.js"></script>

	<script type="text/javascript" src="js/nivo-lightbox/nivo-lightbox.min.js"></script>

	<script type="text/javascript" src="js/owl-carousel/owl.carousel.min.js"></script>

	<script type="text/javascript" src="js/test.js"></script>




	<script type="text/javascript" src="js/jquery-easing/jquery.easing.1.3.js"></script>
	<script type="text/javascript" src="js/wow/wow.min.js"></script>
	<!--<script type="text/javascript" src="js/counterup/counterup.min.js"></script>-->

	<!--<script src="http://cdnjs.cloudflare.com/ajax/libs/waypoints/2.0.3/waypoints.min.js"></script>-->
	<!--<script type="text/javascript" src="js/counterup/jquery.counterup.min.js"></script>-->


	<script type="text/javascript" src="js/isotop/isotope.min.js"></script>
	<script type="text/javascript" src="js/isotop/isotop.function.js"></script>

	<script type="text/javascript" src="js/masonry/masonry.min.js"></script>

	<script type="text/javascript" src="js/mixitup/jquery.mixitup.min.js"></script>
	<script type="text/javascript" src="js/masonry/masonry.pkgd.min.js"></script>
</body>
</html>
